Authors

Rinne, Juha O., Brooks, David J., Rossor, Martin N., Fox, Nick C., Bullock, Roger, Klunk, William E., Mathis, Chester A., Blennow, Kaj, Barakos, Jerome, Okello, Aren A., Rodriguez Martinez de Liano, Sofia, Liu, Enchi, Koller, Martin, Gregg, Keith M., Schenk, Dale, Black, Ronald, Grundman, Michael

Journal

The Lancet. Neurology, Volume: 9, No.: 4, Pages.: 363-372

Year of Publication

2010

Abstract

Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or placebo in a ratio of seven to three in three ascending dose groups (0.5, 1.0, or 2.0 mg/kg). Each dose group was enrolled after safety review of the previous group. Randomisation was by interactive voice response system; masking was achieved with numbered kit allocation. Patients, investigators, study site personnel, sponsor staff, and carers were masked to treatment. Patients received up to six infusions, 13 weeks apart, and had (11)C-PiB PET scans at baseline and at weeks 20, 45, and 78. The primary outcome was the difference between the pooled bapineuzumab group and the pooled placebo group in mean change from screening to week 78 in (11)C-PiB cortical to cerebellar retention ratio averaged across six cortical regions of interest. Analysis was by modified intention to treat. This study is registered with EudraCT, number 2004-004120-12; ISRCTN17517446.; Findings: 28 patients were assigned to bapineuzumab (n=20) or placebo (n=8). 19 patients in the bapineuzumab group and seven in the placebo group were included in the modified intention-to-treat analysis. Estimated mean (11)C-PiB retention ratio change from baseline to week 78 was -0.09 (95% CI -0.16 to -0.02; p=0.014) in the bapineuzumab group and 0.15 (95% CI 0.02 to 0.28; p=0.022) in the placebo group. Estimated mean difference in (11)C-PiB retention ratio change from baseline to week 78 between the bapineuzumab group and the placebo group was -0.24 (95% CI -0.39 to -0.09; p=0.003). Differences between the bapineuzumab group and the placebo group in the individual regions of interest were similar to the overall mean difference. Adverse events were typically mild to moderate in severity and transient. Two patients in the 2.0 mg/kg bapineuzumab group had transient cerebral vasogenic oedema.; Interpretation: Treatment with bapineuzumab for 78 weeks reduced cortical (11)C-PiB retention compared with both baseline and placebo. (11)C-PiB PET seems to be useful in assessing the effects of potential Alzheimer’s disease treatments on cortical fibrillar amyloid-beta load in vivo.; Funding: Elan Pharmaceuticals and Wyeth Research.; 2010 Elsevier Ltd. All rights reserved.

Bibtex Citation

@article{Rinne_2010, doi = {10.1016/s1474-4422(10)70043-0}, url = {http://dx.doi.org/10.1016/s1474-4422(10)70043-0}, year = 2010, month = {apr}, publisher = {Elsevier {BV}}, volume = {9}, number = {4}, pages = {363--372}, author = {Juha O Rinne and David J Brooks and Martin N Rossor and Nick C Fox and Roger Bullock and William E Klunk and Chester A Mathis and Kaj Blennow and Jerome Barakos and Aren A Okello and Sofia Rodriguez Martinez de LIano and Enchi Liu and Martin Koller and Keith M Gregg and Dale Schenk and Ronald Black and Michael Grundman}, title = {11C-{PiB} {PET} assessment of change in fibrillar amyloid-$upbeta$ load in patients with Alzheimer{textquotesingle}s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study}, journal = {The Lancet Neurology} }